Inhaled medication is the cornerstone of medical treatment of COPD. The efficacy of these treatments depends on the optimal use of inhalation devices. This requires not only an impeccable inhalation technique, but above all the selection of an inhaler adapted to the patient. In this article, we describe the specificities of the different inhalation devices and some of the patient's characteristics to be taken into account when selecting an inhaler, in particular the presence of cognitive disorders, impaired dexterity or insufficient inspiratory force.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
How do patients determine when their inhaler is empty? Insights from an analysis of returned inhalers and a patient survey.
BMJ Open Respir Res
December 2024
Chiesi Ltd, Manchester, UK
Background: Inhalers are widely used for the management of asthma and chronic obstructive pulmonary disease. However, there is little knowledge about the extent to which an inhaler is used and when it is disposed of, despite the implications for an individual's health (when used beyond the recommended number of doses (overused)), and medicine wastage, healthcare costs and the environment (when discarded with remaining doses (underused)). To explore inhaler use, we assessed the number of doses remaining in pressurised metered-dose inhalers (pMDIs) returned via a Chiesi Inhaler Recycling scheme.
View Article and Find Full Text PDFInnovative Dual Combination Cospray-Dried Rock Inhibitor/l-Carnitine Inhalable Dry Powder Aerosols.
ACS Bio Med Chem Au
December 2024
The University of Arizona College of Pharmacy, Skaggs Pharmaceutical Sciences Center, Tucson, Arizona 85721, United States.
This study introduces novel cospray-dried (Co-SD) formulations of simvastatin, a Nrf2 activator ROCK inhibitor, with l-carnitine as molecular mixtures in various molar ratios for targeted pulmonary inhalation aerosol delivery in pulmonary hypertension, optimized for excipient-free dry powder inhalers (DPIs). The two components were spray-dried at various molar ratios by using different starting feed solution concentrations and process parameters. In addition to comprehensive physicochemical characterization, in vitro aerosol dispersion performance as DPIs using two FDA-approved DPI devices with different shear stress properties, in vitro viability as a function of dose on 2D human pulmonary cellular monolayers and on 3D small airway epithelia human primary cultures at the air-liquid interface (ALI), and in vitro transepithelial electrical resistance (TEER) at the ALI were conducted.
View Article and Find Full Text PDFA breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview.
Expert Opin Drug Deliv
December 2024
Université de Tours, Centre d'Etude des Pathologies Respiratoires, Tours, France.
Introduction: With the worldwide growing burden of respiratory tract infections (RTIs), innovative therapeutic approaches are in high demand. Inhaled antibodies (Abs) represent a promising avenue, offering targeted treatment options with potentially better therapeutic index compared to traditional delivery methods.
Areas Covered: This comprehensive review summarizes the challenges faced in delivering Abs by (intranasal and pulmonary) inhalation.
A survey of physicians, biomedical researchers and college-educated adults in urban north India about inhaled therapies.
Tuberculosis (Edinb)
December 2024
CSIR-Central Drug Research Institute, Sector 10A, Janakipuram Extension, Lucknow, 226031, UP, India. Electronic address:
We surveyed 15 persons with a medical qualification, 133 graduate students doing biomedical research and 56 students or working people with a college education in any discipline. Questions were designed to gauge awareness about inhaled therapies for tuberculosis (TB), non-tubercular mycobacterial lung disease (NTM-LD) and idiopathic pulmonary fibrosis (IPF). Respondents from six cities in North India, aged between 21 and 57 years answered 20 questions.
View Article and Find Full Text PDFTriple inhaler therapy in adolescents and adults with moderate or severe persistent asthma.
JAAPA
January 2025
Mark L'Eplattenier, Gina Pontrelli, and Carina Loscalzo are assistant professors in the PA program at Hofstra University in Hempstead, N.Y. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Expert guidelines, meta-analyses, and multiple randomized controlled trials have demonstrated the effectiveness of long-acting inhaled antimuscarinic agents (LAMAs) as an additive medication for patients with poorly controlled moderate or severe persistent asthma. LAMAs play an essential role in blocking acetylcholine binding to muscarinic receptors and reducing bronchoconstriction and mucus production. By adding this medication to other combination inhalers, patients can use a triple inhaler to improve FEV1 values and reduce exacerbations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!